Pressmeddelanden från Gubra

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

COURSE OF GUBRA A/S' ANNUAL GENERAL MEETING 2026 09 mar 13:23

AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog 03 mar 14:00

NOTICE TO CONVENE ANNUAL GENERAL MEETING 2026 GUBRA A/S 02 mar 16:14

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 27 feb 07:30

Annual Report 2025: A record year 26 feb 07:30

Gubra submits clinical trial application for First-in-Human study of lead asset GUB-UCN2 10 feb 07:30

Gubra launches Gubra Ventures and appoints Zoë Johnson to lead new venture creation unit 08 jan 13:00

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra 05 jan 07:30

Gubra appoints Dr. Thomas Langenickel as Chief Medical and Development Officer 02 jan 07:30

Gubra Announces Expansion of Facilities to Support Continued Growth Across Its Businesses 17 dec 2025 13:49

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 16 dec 2025 11:30

Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism 08 dec 2025 08:00

Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development 10 nov 2025 21:23

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 10 nov 2025 17:29

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 07 nov 2025 18:03

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 07 nov 2025 07:30

Trading statement Q3-2025: Expanding our R&D activities 06 nov 2025 17:16

Record earnings for Gubra; revised outlook for the CRO business 02 sep 2025 07:30

Gubra Announces Completion of Solar & Battery Park 21 aug 2025 07:30

Interim report H1 2025: Group revenue and earnings record-high 20 aug 2025 17:11

Record quarter for Gubra, but revised outlook for the CRO business 12 aug 2025 10:42

Markus Rohrwild appointed new CEO of Gubra in a planned succession process 10 jul 2025 22:14

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 10 jul 2025 22:07

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 30 jun 2025 09:51

Gubra shares are traded ex-dividend 27 jun 2025 13:09

COURSE OF GUBRA A/S' EXTRAORDINARY GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND 03 jun 2025 07:30

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND 09 maj 2025 07:30

Trading statement Q1-2025: A landmark deal for GUBamy 03 apr 2025 16:17

Gubra Welcomes New Board Members at 2025 AGM 03 apr 2025 14:06

Course of Gubra A/S' Annual General Meeting 2025 01 apr 2025 16:52

Successful Transaction Closure of License Agreement 01 apr 2025 08:45

Gubra announces positive GUBamy Phase 1 interim MAD results 28 mar 2025 22:32

Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra 10 mar 2025 12:57

NOTICE TO CONVENE ANNUAL GENERAL MEETING 2025 03 mar 2025 07:08

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity 28 feb 2025 07:30

Annual Report 2024: Excellent performance across Gubra 15 jan 2025 07:30

Gubra appoints new Chief Operating Officer 30 dec 2024 13:30

Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist 13 nov 2024 18:36

Gubra announces positive GUBamy Phase 1 SAD data (correction)13 nov 2024 17:41

Gubra announces positive GUBamy Phase 1 SAD data 07 nov 2024 07:30

Trading statement Q3-2024: Another strong quarter 31 okt 2024 11:07

Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim 06 sep 2024 21:42

Major shareholder announcement 22 aug 2024 07:30

Interim report H1 2024: Strong performance across Gubra 21 aug 2024 17:12

Gubra raises financial outlook for 2024 10 jul 2024 23:38

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 02 jul 2024 20:25

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 01 jul 2024 07:30

Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class, triple agonist, obesity treatment 28 jun 2024 12:05

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 04 jun 2024 15:30

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 04 jun 2024 15:25

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 07 maj 2024 07:30

Trading statement Q1-2024: Strong start to the year 06 maj 2024 17:15

Gubra raises financial outlook for 2024 17 apr 2024 07:30

Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss 04 apr 2024 12:32

RESOLUTIONS OF GUBRA A/S' ANNUAL GENERAL MEETING 2024 03 apr 2024 21:45

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 03 apr 2024 21:35

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 27 mar 2024 14:45

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 26 mar 2024 22:45

Major shareholder announcement: The Capital Group Companies Inc.25 mar 2024 11:29

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 25 mar 2024 09:56

Major shareholder announcement 06 mar 2024 09:00

NOTICE TO CONVENE ANNUAL GENERAL MEETING 2024 04 mar 2024 21:41

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares 28 feb 2024 07:30

Annual Report 2023 – Revenue in the CRO business growing by 29% to record high level 26 jan 2024 13:33

Gubra concludes the research agreement with UK Biotech 13 dec 2023 17:19

Gubra and Boehringer Ingelheim sign 4th partnership, expanding their successful obesity treatment discovery collaboration 29 nov 2023 12:51

Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity 08 nov 2023 07:30

Trading statement Q3-2023: Continued strong performance 01 nov 2023 11:01

Gubra strengthens Board of Directors 01 nov 2023 10:40

Gubra - Extraordinary general meeting 26 okt 2023 12:35

Gubra enters into a Market Maker Agreement 26 okt 2023 08:01

Gubra raises financial guidance for full-year 2023 24 okt 2023 07:30

Gubra opens its first US office in Boston 09 okt 2023 14:00

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING 06 sep 2023 09:58

Gubra submits clinical trial application (CTA) for first-in-human amylin trial 01 sep 2023 11:41

Completion of share buy-back programme 28 aug 2023 08:15

Gubra resumes its share buy-back programme to hedge incentive scheme obligations 25 aug 2023 07:30

Interim report H1-2023: Strong performance and ahead of expectations 23 aug 2023 16:44

Gubra announces termination of collaboration with Bayer 21 aug 2023 15:29

Gubra A/S announces signing of collaboration agreement with Hemab ApS 15 aug 2023 13:19

Gubra raises financial guidance for full-year 2023 28 jul 2023 19:41

Information on share buy-back programme 30 jun 2023 08:00

Gubra launches share buy-back programme to hedge incentive scheme obligations 29 jun 2023 07:00

Gubra acquires research service provider MiniGut ApS